Tier 2 — strong

Increasing the efficiency of hypolipidemic therapy with the combined use of quercetin in patients with non-alcoholic fatty liver disease on the background of the metabolic syndrome

Lyudmila Kravchenko, Liana Unhurian, Svetlana K Tiuzhinska, Yana Ivanova, Maya Obrazenko, Liudmyla Zahorodnya, Tetiana Yamilova
Ceska a Slovenska farmacie : casopis Ceske farmaceuticke spolecnosti a Slovenske farmaceuticke spolecnosti 2023 72(6):296-302

Bibliography

PubMed
PMID 38346907
DOI
10.5817/CSF2023-6-296
Funding
Funding was not specified in the indexed record or the disclosure metadata available for this entry.
Competing interests
A competing-interest declaration was not available in the indexed record or the disclosure metadata used for this entry.

Study snapshot

DesignComparative adjunct-treatment liver and lipid study
ModelHuman intervention research
Sample86 patients with fatty liver and metabolic syndrome
InterventionRosuvastatin with or without quercetin; abstract dose wording requires full-method clarification
Duration90 days
EndpointsLipid measurements; Oxidative-stress measures; Liver measurements

What the study showed, in plain terms

Published in 2023, this source examined liver and metabolic health. Design: Comparative adjunct-treatment liver and lipid study. Sample/model: 86 patients with fatty liver and metabolic syndrome. The exposure or intervention was Rosuvastatin with or without quercetin; abstract dose wording requires full-method clarification. Follow-up or treatment period: 90 days.

Laboratory liver, lipid, and oxidative-stress measures improved, with the authors reporting greater changes in the combination group.

Allocation and exact dose attribution are unclear in the abstract. Combination therapy and surrogate measures do not establish prevention of liver progression.

Continue with Quercetin Data Center

For topic-level interpretation, read Quercetin for Weight Loss, Blood Sugar and Fatty Liver: Human Evidence. This is a related guide; the citation panel separately identifies articles that directly cite this paper.

Key findings

  • Laboratory liver, lipid, and oxidative-stress measures improved, with the authors reporting greater changes in the combination group.
  • The recorded outcome domains were Lipid measurements; Oxidative-stress measures; Liver measurements.
  • The result applies to the tested exposure: Rosuvastatin with or without quercetin; abstract dose wording requires full-method clarification; 90 days.

What this study can and cannot tell us

  • Allocation and exact dose attribution are unclear in the abstract. Combination therapy and surrogate measures do not establish prevention of liver progression.
  • An individual controlled trial must be interpreted alongside its comparator, sample size, endpoint selection and independent replication. It does not validate a different commercial formulation or a general longevity claim.
  • Source basis: Source check: PubMed abstract and indexed metadata; full methods were not independently confirmed for this entry. Missing method details, funding information or participant denominators are not inferred.

Related papers in the corpus

Tier 1
Effects of Quercetin on Metabolic Dysfunction-Associated Steatotic Liver Disease: A Systematic Review and Meta-Analysis
Dachuan Jin et al. · Food science & nutrition · 2025

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology